Featured Research

from universities, journals, and other organizations

Lazy Eye Treatment Times Could Be Drastically Reduced, New Research Shows

Date:
December 9, 2008
Source:
University of Nottingham
Summary:
Treatment times for amblyopia -- more commonly known as 'lazy eye' -- could be drastically reduced because of new research.

Treatment times for amblyopia — more commonly known as ‘lazy eye’ — could be drastically reduced thanks to research carried out at The University of Nottingham.

Amblyopia is thought to affect up to 2.5 per cent of people and accounts for around 90 per cent of all children’s eye appointments in the UK. Occlusion therapy — patching the normal eye for lengthy periods to ‘train’ the affected eye — is the main treatment for amblyopia. However, this method can be distressing to children, is unpopular with parents and can adversely effect educational development. This type of therapy has been used in various forms since 1743 and has long been considered to only be effective up until late childhood.

The new treatments developed in the Visual Neuroscience Group in the University’s School of Psychology have not only reduced potential treatment times by an unprecedented amount, they have also proved that it is possible to treat amblyopia in adults. Early results suggest gains, that would have required around 120 hours of occlusion therapy to achieve, can be produced after just 10 hours.

Adult test subjects have undertaken challenging visual tasks under computer-controlled conditions. Academics hope that these promising results could be used to develop a child-friendly game that could treat amblyopia. There is also the potential to use these new treatments to supplement occlusion therapy.

The 60,000 project — A Study of Perceptual Learning Effects in Amblyopia — has been funded by the College of Optometrists. Amblyopia is a developmental problem in the brain, not the eye. The part of the brain dealing with vision from the affected eye develops abnormally as a result of atypical visual experience early in life. This results in markedly different levels of vision in each eye which cannot be remedied with spectacles.

As well as looking at potential treatments for the condition, the study examines the level of neural plasticity in the adult brain — the ability of a neural system to change with experience.

The work is being carried out by Andrew Astle, a PhD student at the University.

“The results so far show a drastic improvement on patching, and disprove the long-held belief that adults cannot be treated for this type of condition,” Andrew said. “However, the study is not complete and we’re still looking for subjects to take part in the tests.”

Work set to start in spring 2009 at the University will build on Andrew’s results, examining amblyopia in children and examining the functional and structural organisation of the visual cortex. This EU-wide study has been funded by a European Consortium FP7 grant to the tune of 2.6m Euro. Professor Paul McGraw and Dr Ben Webb in the Visual Neuroscience Group will look at the effects and treatment of amblyopia in children. Other European institutions, including the University of Florence, the Max Planck Institute for Neuroscience and University College London, will examine the condition from the molecular level to its behavioural impact on animal models.

It is thought that results from this study could be translated to other conditions where recovery is limited due to restricted neural plasticity — including brain tumours, stroke, degenerative diseases and trauma.

Professor McGraw said “Andrew’s results suggest that the adult amblyopic visual system retains a great deal more neural plasticity than previously thought. Harnessing this plasticity offers a new way of treating this common condition and opens the door to developing novel pharmacological and behavioural interventions for a range of neurological deficits.”


Story Source:

The above story is based on materials provided by University of Nottingham. Note: Materials may be edited for content and length.


Cite This Page:

University of Nottingham. "Lazy Eye Treatment Times Could Be Drastically Reduced, New Research Shows." ScienceDaily. ScienceDaily, 9 December 2008. <www.sciencedaily.com/releases/2008/12/081209111520.htm>.
University of Nottingham. (2008, December 9). Lazy Eye Treatment Times Could Be Drastically Reduced, New Research Shows. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/12/081209111520.htm
University of Nottingham. "Lazy Eye Treatment Times Could Be Drastically Reduced, New Research Shows." ScienceDaily. www.sciencedaily.com/releases/2008/12/081209111520.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins